研究目的
To evaluate the efficacy and safety of half-dose photodynamic therapy (PDT) treating diffused retinal pigment epitheliopathy (DRPE) guided by simultaneous angiography and optical coherence tomography (OCT).
研究成果
Simultaneous FA, ICGA, and OCT facilitated more comprehensive guidance for half-dose PDT treatment in all 48 eyes with DRPE, ensuring its efficacy and safety. The BCVA improvement, which emerged at 6 months, later than general chronic CSC, appeared to be attributable to the restoration of the outer retinal structure.
研究不足
The limitations of this study included the small sample size, retrospective design, and lack of control group. Future investigations could include other examinations like OCT angiography, multifocal electroretinography, and microperimetry for more comprehensive information.
1:Experimental Design and Method Selection:
A retrospective case series design was used. Forty-eight consecutive patients with DRPE treated with half-dose PDT underwent follow-up at baseline, 3 months, 6 months, 12 months, and 24 months. Simultaneous FA, ICGA, and OCT were used for the treatment and follow-up.
2:Sample Selection and Data Sources:
Patients presenting with chronic DRPE from April 2011 to December 2015 were recruited and followed up for at least 24 months after half-dose PDT administration.
3:List of Experimental Equipment and Materials:
Spectralis? HRA + OCT system (Heidelberg Engineering, Heidelberg, Germany), Opal Photoactivator laser (Lumenis, Beijing, China), ocular fundus laser lens (Ocular Inc., Bellevue, WA, USA).
4:Experimental Procedures and Operational Workflow:
Patients were treated with half-dose PDT and followed up at specified intervals. BCVA, OCT, FA, and ICGA were performed at each visit.
5:Data Analysis Methods:
SPSS software version 20.0 and GraphPad Prism 6.0 were used for data analyses. Paired t-test, analysis of variance, and non-parametric Wilcoxon signed-rank test were used to compare differences. Linear regression analyses were performed to assess associations.
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容